Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019
October 31 2019 - 4:01PM
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its
third quarter 2019 financial results on Thursday, November 7, 2019
before market opens. Management will conduct a conference call and
live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss
the financial results and to provide a business update.
Dial-in InformationU.S. Dial-in
Number: (888) 645-5785International Dial-in Number:
(970) 300-1531Conference ID: 8189178
Replay InformationU.S. Dial-in
Number: (855) 859-2056Replay International Dial-in
Number: (404) 537-3406Conference ID: 8189178
The dial-in replay will be available for 7 days
following the call. An audio webcast will be available online in
the investor relations section of the company website at
www.lexpharma.com/investors, with a webcast replay accessible for
14 days after the call.
About Lexicon
Pharmaceuticals
Lexicon is a fully integrated biopharmaceutical
company with a mission of pioneering medicines that transform
patients’ lives. Through its Genome5000™ program, Lexicon
scientists studied the role and function of nearly 5,000 genes and
identified more than 100 protein targets with significant
therapeutic potential in a range of diseases. Through the precise
targeting of these proteins, Lexicon is pioneering the discovery
and development of innovative medicines to safely and effectively
treat disease. In addition to its first commercial product,
XERMELO, Lexicon has a pipeline of promising drug candidates in
clinical and preclinical development in diabetes and metabolism,
oncology and neuropathic pain. For additional information, please
visit www.lexpharma.com.
Safe Harbor Statement
This press release contains “forward-looking
statements,” including statements relating to Lexicon’s long-term
outlook on its business, including the clinical development of, the
regulatory filings for, and the potential therapeutic and
commercial potential of XERMELO (telotristat ethyl), Zynquista
(sotagliflozin), and LX9211. In addition, this press release also
contains forward looking statements relating to Lexicon’s growth
and future operating results, discovery, development and
commercialization of products, strategic alliances and intellectual
property, as well as other matters that are not historical facts or
information. All forward-looking statements are based on
management’s current assumptions and expectations and involve
risks, uncertainties and other important factors, specifically
including Lexicon’s ability to meet its capital requirements,
successfully commercialize XERMELO, successfully complete the
transition from Sanofi of responsibility for ongoing clinical
studies and other activities relating to sotagliflozin,
successfully conduct preclinical and clinical development and
obtain necessary regulatory approvals of telotristat ethyl,
sotagliflozin, LX9211 and its other potential drug candidates on
its anticipated timelines, achieve its operational objectives,
obtain patent protection for its discoveries and establish
strategic alliances, as well as additional factors relating to
manufacturing, intellectual property rights, and the therapeutic or
commercial value of its drug candidates. Any of these risks,
uncertainties and other factors may cause Lexicon’s actual results
to be materially different from any future results expressed or
implied by such forward-looking statements. Information identifying
such important factors is contained under “Risk Factors” in
Lexicon’s annual report on Form 10-K for the year ended December
31, 2018, as filed with the Securities and Exchange Commission.
Lexicon undertakes no obligation to update or revise any such
forward-looking statements, whether as a result of new information,
future events or otherwise.
For Investor Inquiries:
Kimberly Lee, D.O.Head of Investor Relations and
Corporate StrategyLexicon Pharmaceuticals(281)
863-3383klee@lexpharma.com
For Media Inquiries:
Chas SchultzExecutive Director, Corporate
Communications and Patient AdvocacyLexicon Pharmaceuticals(281)
863-3421cschultz@lexpharma.com
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Lexicon Pharmaceuticals (NASDAQ:LXRX)
Historical Stock Chart
From Apr 2023 to Apr 2024